A brief history of the global effort to develop a preventive HIV vaccine

被引:105
作者
Esparza, Jose [1 ]
机构
[1] Bill & Melinda Gates Fdn, Seattle, WA 98102 USA
关键词
HIV; AIDS; History; Vaccines; Global effort; IMMUNODEFICIENCY-VIRUS TYPE-1; CELLULAR IMMUNE-RESPONSES; SIV DNA VACCINE; HUMAN MONOCLONAL-ANTIBODY; CYTOTOXIC T-LYMPHOCYTES; VECTOR-BASED VACCINES; CD4; BINDING-SITE; PHASE-I TRIAL; AIDS VACCINE; NEUTRALIZING ANTIBODIES;
D O I
10.1016/j.vaccine.2013.05.018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Soon after HIV was discovered as the cause of AIDS in 1983-1984, there was an expectation that a preventive vaccine would be rapidly developed. In trying to achieve that goal, three successive scientific paradigms have been explored: induction of neutralizing antibodies, induction of cell mediated immunity, and exploration of combination approaches and novel concepts. Although major progress has been made in understanding the scientific basis for HIV vaccine development, efficacy trials have been critical in moving the field forward. In 2009, the field was reinvigorated with the modest results obtained from the RV144 trial conducted in Thailand. Here, we review those vaccine development efforts, with an emphasis on events that occurred during the earlier years. The goal is to provide younger generations of scientists with information and inspiration to continue the search for an HIV vaccine. (c) 2013 The Author. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:3502 / 3518
页数:17
相关论文
共 369 条
[31]  
BRANDT EN, 1984, PUBLIC HEALTH REP, V99, P433
[32]   Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial [J].
Buchbinder, Susan P. ;
Mehrotra, Devon V. ;
Duerr, Ann ;
Fitzgerald, Daniel W. ;
Mogg, Robin ;
Li, David ;
Gilbert, Peter B. ;
Lama, Javier R. ;
Marmor, Michael ;
del Rio, Carlos ;
McElrath, M. Juliana ;
Casimiro, Danilo R. ;
Gottesdiener, Keith M. ;
Chodakewitz, Jeffrey A. ;
Corey, Lawrence ;
Robertson, Michael N. .
LANCET, 2008, 372 (9653) :1881-1893
[33]   A Blueprint for HIV Vaccine Discovery [J].
Burton, Dennis R. ;
Ahmed, Rafi ;
Barouch, Dan H. ;
Butera, Salvatore T. ;
Crotty, Shane ;
Godzik, Adam ;
Kaufmann, Daniel E. ;
McElrath, M. Juliana ;
Nussenzweig, Michel C. ;
Pulendran, Bali ;
Scanlan, Chris N. ;
Schief, William R. ;
Silvestri, Guido ;
Streeck, Hendrik ;
Walker, Bruce D. ;
Walker, Laura M. ;
Ward, Andrew B. ;
Wilson, Ian A. ;
Wyatt, Richard .
CELL HOST & MICROBE, 2012, 12 (04) :396-407
[34]   Scaffolding to build a rational vaccine design strategy [J].
Burton, Dennis R. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (42) :17859-17860
[35]   A Boost for HIV Vaccine Design [J].
Burton, Dennis R. ;
Weiss, Robin A. .
SCIENCE, 2010, 329 (5993) :770-773
[36]   Public health - A sound rationale needed for phase IIIHIV-1 vaccine trials [J].
Burton, DR ;
Desrosiers, RC ;
Doms, RW ;
Feinberg, MB ;
Gallo, RC ;
Hahn, B ;
Hoxie, JA ;
Hunter, E ;
Korber, B ;
Landay, A ;
Lederman, MM ;
Lieberman, J ;
McCune, JM ;
Moore, JP ;
Nathanson, N ;
Picker, L ;
Richman, D ;
Rinaldo, C ;
Stevenson, M ;
Watkins, DI ;
Wolinsky, SM ;
Zack, JA .
SCIENCE, 2004, 303 (5656) :316-316
[37]   HIV vaccine design and the neutralizing antibody problem [J].
Burton, DR ;
Desrosiers, RC ;
Doms, RW ;
Koff, WC ;
Kwong, PD ;
Moore, JP ;
Nabel, GJ ;
Sodroski, J ;
Wilson, IA ;
Wyatt, RT .
NATURE IMMUNOLOGY, 2004, 5 (03) :233-236
[38]   An AIDS vaccine: no time to give up [J].
Burton, DR ;
Desrosiers, RC ;
Johnson, PR ;
Koff, WC .
LANCET, 2004, 364 (9449) :1938-1938
[39]   Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-Seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 vaccine study [J].
Cao, H ;
Kaleebu, P ;
Hom, D ;
Flores, J ;
Agrawal, D ;
Jones, N ;
Serwanga, J ;
Okello, M ;
Walker, C ;
Sheppard, H ;
El-Habib, R ;
Klein, M ;
Mbidde, E ;
Mugyenyi, P ;
Walker, B ;
Ellner, J ;
Mugerwa, R .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (06) :887-895
[40]   Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: Relevance to HIV-1 vaccine trials in Uganda [J].
Cao, HY ;
Mani, I ;
Vincent, R ;
Mugerwa, R ;
Mugyenyi, P ;
Kanki, P ;
Ellner, J ;
Walker, BD .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (05) :1350-1356